Rapamycin drug tested for rare castleman disease
NCT ID NCT03933904
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests the drug sirolimus (rapamycin) in 7 people with idiopathic multicentric Castleman disease who have not improved with standard therapy. The goal is to see if sirolimus can improve symptoms like fatigue, fever, and night sweats, and shrink enlarged lymph nodes. It is a small, early-stage trial with no comparison group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sirolimus (also known as rapamycin)
- What this could lead to
- If it works, this could point toward a new treatment option for people with idiopathic multicentric Castleman disease who have not responded to standard therapies.
- What could go wrong
- This is a very small early-phase trial with only 7 participants, so results may not apply to everyone. The drug may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTLEMAN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.